# Table of Clinical Trials that use Response Adaptive Designs
Here's the updated table with trials listed alphabetically, numbered, and including an empty "Notes" column:

| #  | Trial Name/ID                           | Status     | Phase     | General RA Method        | Sample Size                 | Number of Arms                   | Outcome                        | Condition                  | Primary Endpoint                                                                                             | Notes | DOI                                                                                                      |
|----|-----------------------------------------|------------|-----------|--------------------------|-----------------------------|----------------------------------|--------------------------------|-----------------------------|----------------------------------------------------------------------------------------------------------|-------|----------------------------------------------------------------------------------------------------------|
| 1  | ABT-089       |    completed        |    II        |       BRAR                   |        337                      | 7                                |      Alzheimer’s Disease Assessment Scale, cognition subscale (ADAS-Cog) total score                          |     Mild Alzheimer                        | Alzheimer’s Disease Assessment Scale, cognition subscale (ADAS-Cog) total score                         |  stped early for futility     | [DOI link](https://doi.org/10.1097/WAD.0000000000000093)                                               |
| 2  | Adverse Karyotype Acute Myeloid Leukemia   | completed    |  III         |     BRAR                     |     34                         | 3                                | Binary                        |          Leukemia                   | Complete remission without nonhematologic grade 4 toxicity by 50 days                                   |       | [DOI link](https://doi.org/10.1200/jco.2003.11.016)                                                    |
| 3  | ADORE trial                             | completed  |  III | BRAR                     | 1100                         | 2                                | Binary                        | Preterm birth               | earliest preterm birth (<34 weeks) (ePTB)                                                              |       | [DOI link 1](https://doi.org/10.1186/s12884-017-1244-5), [DOI link 2](https://doi.org/10.1080/10543406.2022.2148161), [DOI link 3](https://doi.org/10.1016/j.eclinm.2021.100905) |
| 4  | ARREST trial                            |            |           |                          |                              | 2                                | Survival                     |                             | Number of patients who survived to hospital discharge                                                   |       | [DOI link 1](https://doi.org/10.1016/j.ahj.2020.07.006), [DOI link 2](https://doi.org/10.1016%2FS0140-6736(20)32338-2) |
| 5  | ASTIN                                   |            |           |                          |                              | 16                               |                                |                             | Change from baseline to day 90 on the Scandinavian Stroke Scale                                         |       | [DOI link](https://doi.org/10.1161/01.STR.0000092527.33910.89)                                         |
| 6  | ATTACC                                  |            |           |                          |                              | 2                                | Ordinal Categorical           |                             | Three possible outcomes based on the worst status of each patient through day 30                        |       | [DOI link](https://doi.org/10.1177/1740774520943846)                                                   |
| 7  | AWARD-5                                 |            |           |                          |                              | 9                                |                                |                             | Clinical utility index (CUI) with possible values from 0 to 6                                           |       | [DOI link](https://doi.org/10.1111/dom.12305)                                                          |
| 8  | BATTLE                                  |            |           |                          |                              | 4                                |                                |                             | 8-week disease control rate (DCR)                                                                      |       | [DOI link](https://doi.org/10.1158/2159-8274.CD-10-0010)                                               |
| 9  | BATTLE-2                                |            |           |                          |                              |                                  |                                |                             |                                                                                                          |       | [DOI link](https://doi.org/10.1200/JCO.2015.66.0084)                                                   |
| 10 | ESETT                                   |            |           |                          |                              | 3                                | Binary                        |                             | Clinical cessation of status epilepticus                                                                |       | [DOI link](https://doi.org/10.1111/epi.12288)                                                          |
| 11 | endTB                                   |            |           |                          |                              | 6                                | Binary                        |                             | Treatment success at 73 weeks after randomisation                                                       |       | [DOI link](https://doi.org/10.1177/1740774516665090)                                                   |
| 12 | GBM AGILE                               |            |           |                          |                              | Multi-arm                        | Binary                        |                             | Overall survival                                                                                        |       | [DOI link](https://doi.org/10.1158/1078-0432.CCR-17-0764)                                              |
| 13 | Ghrelin Agonist TZP-101                 |            |           |                          |                              | 8                                | Time-to-Event                 |                             | Time to first bowel movement                                                                           |       | [DOI link](https://doi.org/10.1007%2FDCR.0b013e3181b54166)                                             |
| 14 | I-SPY 2                                 |            |           |                          |                              | Multi-arm                        |                                |                             | Pathologic complete response (pCR)                                                                     |       | [DOI link 1](https://doi.org/10.1038/clpt.2009.68), [DOI link 2](https://doi.org/10.1056/NEJMoa1513749), [DOI link 3](https://doi.org/10.1056/NEJMoa1513750) |
| 15 | insulin sliding vs weight-based regimen |            |           |                          |                              | 3                                | Continuous                    |                             | Hospital length of stay                                                                                |       | [DOI link](https://doi.org/10.1177%2F1740774511398368)                                                 |
| 16 | ketamine in LL-TRD                      |            |           |                          |                              | 5                                |                                |                             | Treatment response 50% improvement on depression rating scale                                           |       | [DOI link 1](https://doi.org/10.1038/s41386-021-01242-9), [DOI link 2](https://doi.org/10.1016/j.conctc.2019.100432)                                              |
| 17 | leborexant for treatment of insomnia    |            |           |                          |                              | 7                                |                                |                             | Utility function integrating sleep efficiency and the scale (zero or >1)                               |       | [DOI link](https://doi.org/10.5664/jcsm.6800)                                                          |
| 18 | PAIN-CONTRoLS                           |            |           |                          |                              | 4                                |                                |                             | Combination of two endpoints: at least 50% pain reduction in Likert scale AND observed percentage of patients who quit |       | [DOI link 1](https://doi.org/10.1016/j.conctc.2023.101220), [DOI link 2](https://doi.org/10.1001/jamaneurol.2020.2590), [DOI link 3](https://doi.org/10.1186/s13063-016-1544-5) |
| 19 | RACE                                    |            |           |                          |                              | 4                                |                                |                             | Sequential organ failure assessment score at 48 hours from enrollment                                   |       | [DOI link](https://doi.org/10.1001/jamanetworkopen.2018.6076)                                          |
| 20 | REMAP-CAP                               |            |           |                          |                              | 16 domains, 56 arms in total     | Binary                        |                             | 90-day mortality                                                                                        |       | [DOI link](https://doi.org/10.1513/AnnalsATS.202003-192SD)                                             |
| 21 | SHINE                                   |            |           |                          |                              | 2                                | Binary                        |                             | Number of participants with a favourable modified Rankin scale (yes/no --> dichotomised)                |       | [DOI link 1](https://doi.org/10.1186/s13063-015-0574-8), [DOI link 2](https://doi.org/10.1111/ijs.12045) |
| 22 | SPRINT                                  |            |           |                          |                              | 6                                |                                |                             | Change from baseline in the mean 24-hour average general pain intensity (AGPI) score                    |       | [DOI link](https://doi.org/10.1097/j.pain.0000000000000983)                                            |
| 23 | STURDY                                  |            |           |                          |                              | 4                                | Time-to-Event                 |                             | Time to first fall or death (whichever comes first)                                                    |       | [DOI link](https://doi.org/10.1016/j.cct.2018.08.004)                                                  |
| 24 | tobacco cessation                       |            |           |                          |                              | 2                                | Binary                        |                             | Biochemically verified abstinence                                                                       |       | [DOI link 1](https://doi.org/10.1001/jamainternmed.2022.7170), [DOI link 2](https://doi.org/10.1186/s13063-017-2119-9)                                                 |
